Keros Q3 net loss $23.5M; cash runway extended to Q1 2025

Keros Therapeutics, Inc.

2022-Q3 EPS reported -$3.05

Net loss of $23.5M in Q3 2022 vs $20.3M in Q3 2021, driven by higher R&D and G&A costs.
R&D expenses $21.0M (+$6.2M YoY); G&A expenses $6.9M (+$1.6M YoY).
Cash and cash equivalents $239.4M at Sep 30, 2022; ATM proceeds extend runway into Q1 2025.
KER-012 Phase 1 data presented; Phase 2 PAH trial design expected early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Keros Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income net loss of $23.5 million.

Period: the quarter ended September 30, 2022
Net income: net loss of $23.5 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $23.5 million in the third quarter of 2022 as compared to a net loss of $20.3 million in the third quarter of 2021.

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-22-000054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.